deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02477826

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb

Conditions Non-Small Cell Lung Cancer
Interventions Carboplatin Cisplatin Gemcitabine Ipilimumab Nivolumab Paclitaxel Pemetrexed
Updated 34 times since 2017 Last updated: Oct 21, 2025 Started: Aug 5, 2015 Primary completion: Oct 25, 2024 Completion: Oct 25, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-Small Cell Lung Cancer and is currently completed. Bristol-Myers Squibb leads this study, which shows 34 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Sep 2019 · 9 months · monthly snapshot~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

34 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  3. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 29 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  7. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  9. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  10. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  12. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  13. Oct 2021 — Apr 2022 [monthly]

    Recruiting PHASE3

  14. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  15. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  16. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  17. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  18. Sep 2019 — Sep 2020 [monthly]

    Recruiting PHASE3

  19. Dec 2018 — Sep 2019 [monthly]

    Recruiting PHASE3

  20. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  21. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  22. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  23. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  24. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  25. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  26. May 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  27. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE3

  28. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  29. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi-shi, Japan , Allentown, United States , Amsterdam, Netherlands , Angers, France , Athens, Greece , Atlanta, United States , Avellino, Italy , Bad Berka, Germany , Barcelona, Spain , Barretos, Brazil and 233 more locations